ClinicalTrials.gg
Enrolling by invitationNCT06197841NFLMSUpdated Jan 9, 2024

Neurofilament Light Chain as Diagnostic and Prognostic Marker in naïve Multiple Sclerosis Patients

An observational study in Role of Neurofilment in Diagnosis of Multiple Sclerosis, sponsored by Assiut University. Enrolling by invitation at 1 site in Egypt. Open to participants aged 16 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Assiut University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
85
Ages
16 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cognitive Dysfunction by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Cognitive Dysfunction · Assiut University.

Started
2023
the only one that year
Observational
8 of 10
6 open now
Registered
5th of 10
by date

Among the 10 studies in Cognitive Dysfunction by Assiut University, this one is the only one that started in 2023, is one of 8 observational ones, and was the 5th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

6 of the 10 studies in Cognitive Dysfunction by Assiut University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 16 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cognitive Dysfunction by Assiut University, or all of them as a file.
02

Study summary

Neurofilament protein detected in the serum appears to be a good marker for the extent of active neurodegeneration. Chitinase may also be a good marker reflecting the degree of astrocyte activation, or damage in active lesions (Paul et al, 2018).These markers have some clinical value for diagnosis and monitoring of disease activity. NfL can be objectively measured and quantified, it is highly sensitive to neurodegenerative processes and its concentration changes as the disease worsens or improves (Disanto et al., 2017). Numerous studies have shown that NfL levels increase during MS relapses and correlate with MRI lesion development (Disanto et al., 2016, 2017; Novakova et al., 2017), disease activity, (Thebault et al., 2020). Cognitive impairment is common in the early stages of multiple sclerosis, mainly affecting attention, working memory, and information processing speed, but also memory, inhibition, and conceptualisation. Poor performance is common but remains subtle and does not significantly affect the quality of life at this stage. However, many studies shows that these deficits reflect the destruction both within and outside lesions, and that they may therefore be considered as a severity marker in the early stages of multiple sclerosis. (Lengenfelder et al., 2005).

The aim of the work is to detect the role of serum NFL and chitinase as biomarkers in the diagnosis and prognosis of newly diagnosed multiple sclerosis patients, and to estimate the incidence of cognitive impairment and their relationship with the NFL in newly diagnosed MS patients.

Read the detailed description

Many immunological studies have been performed with the aim to identify MS specific biomarkers and disease mechanisms and to find markers able to predict clinical disease course and outcome (Housley et al, 2015) Besides MRI and markers related to therapy (induction of blocking antibodies) or JC virus infection, they include markers for neurodegeneration, such as neurofilaments, markers for astrocytic activation (eg. chitinase or GFAP). Neurofilament protein detected in the serum or cerebrospinal fluid appears to be a good marker for the extent of active neurodegeneration, but this is not MS specific. Chitinase may be a good marker for active disease in RRMS, reflecting the degree of astrocyte activation, or damage in active lesions (Paul et al, 2018).These markers have some clinical value for diagnosis and monitoring of disease activity. Cognitive impairment is common in the early stages of multiple sclerosis, mainly affecting attention, working memory, and information processing speed, but also memory, inhibition, and conceptualisation. Poor performance is common but remains subtle and does not significantly affect the quality of life at this stage. However, many studies shows that these deficits reflect the destruction both within and outside lesions, and that they may therefore be considered as a severity marker in the early stages of multiple sclerosis. (Lengenfelder et al., 2005).Aim of the work The aim of the work is to detect the role of serum neurofilament light chain and chitinase as well as cognitive impairment as biomarkers in the diagnosis and prognosis of newly diagnosed multiple sclerosis patients, and to estimate the incidence of cognitive impairment and their relationship with the NFL in newly diagnosed MS patients.Study Design This study is a cross-sectional, prospective, observational study. Subjects All newly diagnosed cases With MS patients attending different MS unites in Assiut governorate will be recruited and all eligible patients will be included.

Inclusion criteria:

All patients newly diagnosed MS according to the 2017-McDonalds criteria.

Exclusion criteria:

  1. patients who are already diagnosed as MS and on treatment.
  2. Presence of other disorder or on medications that may affect the neurological or cognitive disorders.
  3. Patients failed to commit to the follow up visits and regular MRI scans
  4. Patients refused to sign the written informed consent

Patients who will meet the inclusion and exclusion criteria will be assessed in the 1st visit by direct interview followed by clinical examination and neuropsychological assessments as well as laboratory assessment. Baseline MRI scans will be obtained at the first visit and 12 months. In the follow up visits every 6 months for 1and half year at least with assessment for all previous will be repeated to detect early signs of progression.Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...):

Demographic data: age at presentation and age at onset, sex, education years and special habits Clinical data: duration of illness, until diagnosis number of relapses/year and their features.

Clinical assessment: EDSS, 9-hole pig test, 25-feet walking test.

Clinical rating scales :

Cognitive assessment using the Brief International Cognitive Assessment for Multiple sclerosis (BICAMS) with the Arabic validated version (8) that include:

Symbol Digit Modalities Test (SDMT) (Langdon et al. 2012) for evaluating the information processing speed.

California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory.

Brief Visual Memory Test (BVMT) for evaluating visual learning and memory.

Multiple sclerosis Quality of life MSQoL-54 questionnaire (10) with sub scales that measures physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function.

Hamilton depression rating-17-item version (HAM-D 17).

Laboratory investigation:

CSF Oligoclonal band, Serum light chain Neurofilament using PCR Research outcomes The primary outcome is the detection of neurofilament as diagnostic and prognostic inflammatory markers in newly diagnosed MS patients.

Secondary outcome measure is incidence of depression, cognitive impairment in newly diagnosed MS patients.

Follow up of each patient every 6 months using the same previous scales

03

Conditions studied

  • Role of Neurofilment in Diagnosis of Multiple Sclerosis

Keywords

  • Naïve multiple sclerosis patients
  • cognitive impairment
  • Neurofilment light chain
  • Chitinase
  • diagnosis and predictor for outcome
04

Who can participate

Ages eligible
16 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Naïve Patients who will meet the inclusion and exclusion criteria of MS will be assessed in the 1st visit by direct interview followed by clinical examination and neuropsychological assessments as well as laboratory assessment. Baseline MRI scans will be obtained at the first visit and 12, months follow up. In the follow up visits every 6 months for 1and half year at least with assessment for all previous will be repeated to detect early signs of progression.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients newly diagnosed MS according to the 2017-McDonalds criteria.

Exclusion criteria

Exclusion criteria:

  1. patients who are already diagnosed MS and under DMTs treatment
  2. Presence of other disorder or on medications that may affect the neurological or cognitive disorders.
  3. Patients failed to commit to the follow up visits and regular MRI scans
  4. Patients refused to sign the written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
85 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The primary outcome is the detection of neurofilament light chain as diagnostic and prognostic inflammatory markers in newly diagnosed MS patients.

    Assessment of the serum level of NFL at base line before starting DMT and correlate it with motor disability, cognitive impairment after one and half year

    Time frame: 1 and half year

Secondary outcomes

  1. Assessment of the incidence of cognitive impairment among naive multiple sclerosis patients and their correlation with neurofilment light chain

    Assessment of cognitive impairment of the MS Patients using BICAMS

    Time frame: 1 and half year

07

Study locations

1 site
  • Ahmed El menshawy
    Assiut, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 12 months is below that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2023
First posted
Jan 9, 2024
StartActual
Dec 1, 2023
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 2024
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06197841
Lead sponsor
Assiut University
Collaborators
Al-Azhar University
Responsible party
Eman M. Khedr (professor of Neurology, Assiut University) — Principal investigator
First posted
Jan 9, 2024
Start date
Dec 1, 2023
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jan 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion